On the way towards the Sustainable Development Goal (SDG) for health, Europe has one important battle to take on: reducing the proportion of those living with undiagnosed HIV and viral hepatitis. Current status in the EU/EEA: one in seven people living with HIV are unaware of their infection, up to four out of 5 people living with hepatitis B and three out of four people with hepatitis C infection have not yet been diagnosed.
This issue covers the period 6-12 October 2019 and includes updates on Ebola virus disease, extensively drug-resistant Klebsiella pneumoniae, West Nile virus, mass gathering monitoring (Japan, Rugby World Cup 2019), Poliomyelitis, Measles, Zika virus disease, seasonal influenza, XDR-Typhoid fever.
In 2017, 8.3% (11 787) of the patients who stayed in intensive-care units (ICUs) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection, or urinary tract infection).
Carbapenem resistance in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli poses a significant threat to patients and healthcare systems in all European Union/European Economic Area (EU/EEA) countries. Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of treatment options.
ECDC is organising a short course on “Control of multidrug-resistant micro-organisms (MDROs) in health care settings”. This training opportunity is addressed at healthcare professionals from European Union (EU) and European Economic Area (EEA) countries with current or future responsibility for the prevention and control of healthcare-associated infections (HAIs) due to MDROs working at national or local level. The course is offered by invitation only and participants are identified through the ECDC Coordinating Competent Bodies.